Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (“Ampersand”) announce they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion. Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash.
Read the full article: Avid Bioservices to Be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1B Transaction //
Source: https://www.globenewswire.com/news-release/2024/11/06/2976216/0/en/Avid-Bioservices-to-be-Acquired-by-GHO-Capital-Partners-and-Ampersand-Capital-Partners-in-1-1-Billion-Transaction.html